Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase NA 4Phase 2 4Phase 4 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Agnosia 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Ketorolac × Clear all
NCT05597878 2026-05-26

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Wake Forest University Health Sciences

Phase 2/3 Suspended
100 enrolled
Genitourinary

Agnosia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡